Elevance Q3 revenue $50.4B, adjusted EPS $6.99; raises FY26 adjusted EPS guidance to at least $29.00

Elevance Health, Inc.

Q3 operating revenue $50.4B, up 0.7% YoY; diluted EPS $6.27 and adjusted EPS $6.99, including a net non-operating benefit of $1.85 per share.
FY2026 guidance raised to at least $22.00 diluted EPS and at least $29.00 adjusted EPS, cash flow at least $6.5B; 2027 adjusted EPS growth seen at least 12% off $26.75 baseline.
Health Benefits revenue $43.4B (+3%) but operating gain fell to $0.4B from $0.6B on targeted investments; margin 1.0% vs 1.4%; membership 44.9M, down 487k YoY.
Carelon revenue $19.3B (+5%), operating gain $0.9B (+17%) on risk-based solutions and specialty pharmacy; benefit expense ratio improved 70 bps to 90.6%.
Q4 dividend $1.72/share payable Dec 18, 2026 to holders of record Dec 4; Q3 buybacks 0.8M shares for $330M at $398.75 average; $5.0B authorization remains.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.